Alignment Healthcare Past Earnings Performance
Past criteria checks 3/6
Alignment Healthcare has been growing earnings at an average annual rate of 20.7%, while the Healthcare industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 29.6% per year. Alignment Healthcare's return on equity is 9.6%, and it has net margins of 0.5%.
Key information
20.70%
Earnings growth rate
23.17%
EPS growth rate
| Healthcare Industry Growth | 8.50% |
| Revenue growth rate | 29.59% |
| Return on equity | 9.57% |
| Net Margin | 0.47% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Apr 30
ALHC: Lofty Future P/E And Margin Uncertainty Will Limit Long Term Upside
Analysts have lifted their price target on Alignment Healthcare by about $1.38 to roughly $19.38. The change reflects updated views on fair value, a slightly higher discount rate, adjustments to expected revenue growth and profit margin, and a higher future P/E multiple in light of recent research updates from major firms.
Narrative Update • Apr 14
ALHC: Higher Revenue And Margin Assumptions Will Support Earnings Visibility
Narrative Update on Alignment Healthcare Analyst price targets for Alignment Healthcare have moved higher by several dollars per share, with researchers citing adjustments to revenue growth, profit margin assumptions and P/E expectations as key reasons for the updated views. Analyst Commentary Across recent research, bullish analysts have been lifting their price targets on Alignment Healthcare by several dollars per share.Seeking Alpha • Apr 08
Alignment Healthcare's Diagnosis Improves After Industry Developments, But Not Enough For An Upgrade
Summary Alignment Healthcare is reaffirmed as a 'hold' due to extreme valuation despite strong operational momentum and recent positive industry news. ALHC's membership grew to 236,300 in 2025, driving revenue up to $3.95 billion and sharply improving profitability metrics, including near break-even net loss. 2026 guidance calls for further membership and revenue growth, with EBITDA expected to rise to $133–$163 million, aided by a 2.48% CMS payment increase in 2027. While margin compression may occur from reduced prior authorization requirements, ALHC's data-driven model and market expansion position it well for long-term share gains. Read the full article on Seeking Alpha
Narrative Update • Mar 31
ALHC: Membership And Retention Trends Will Support Margin Recovery Outlook
Analysts have nudged the average price target for Alignment Healthcare slightly higher to about $25.50, citing updated models that reflect recent target increases across several firms and refinements to growth, margin, and future P/E assumptions. Analyst Commentary Recent Street research on Alignment Healthcare centers on refreshed models and higher price targets, with bullish analysts pointing to membership trends and updated out year estimates as key inputs.Narrative Update • Mar 17
ALHC: Strong AEP Execution And Membership Gains Will Support Earnings Visibility
Analysts have lifted Alignment Healthcare's average price target by $10 to $30, citing updated models that factor in stronger AEP sales and retention, higher projected 2026 membership, and extended estimates through 2030. Analyst Commentary Recent Street research points to a cluster of higher price targets on Alignment Healthcare, with several firms revisiting their models in light of updated membership and sales assumptions.Narrative Update • Mar 03
ALHC: Membership And Retention Momentum Will Drive Margin Recovery Potential
Analyst price targets for Alignment Healthcare have been lifted by several firms in recent weeks, and our fair value estimate has moved from $21.04 to $25.42 as analysts factor in updated membership expectations and refreshed multi year financial models. Analyst Commentary Recent Street research around Alignment Healthcare has been active, with several firms adjusting their price targets and extending their financial models.Narrative Update • Feb 17
ALHC: Strong AEP Sales And Retention Are Expected To Support Earnings Visibility
Analysts have raised their average price target for Alignment Healthcare to $30, pointing to updated models that factor in stronger AEP sales, better member retention into 2026, and extended estimates through 2030. Analyst Commentary Recent Street research on Alignment Healthcare has centered on higher price targets and refreshed models that extend several years out, reflecting growing attention to the company’s execution on enrollment and retention.Narrative Update • Feb 02
ALHC: Strong Q4 2025 Enrollment Trends Support Long-Term Earnings Visibility
Narrative Update on Alignment Healthcare The analyst price target for Alignment Healthcare has moved to US$30.00, with analysts pointing to refreshed models that reflect recent enrollment trends, updated membership assumptions into 2026, and extended earnings estimates through 2030. Analyst Commentary Bullish analysts have recently refreshed their models on Alignment Healthcare and lifted price targets, citing updated assumptions around member growth, retention, and extended earnings visibility out to 2030.Narrative Update • Jan 19
ALHC: Strong Q4 2025 Enrollment And Retention Will Drive Long-Term Upside
Analysts have lifted their price targets on Alignment Healthcare by roughly $6 to around $29 per share, citing updated models that factor in strong Q4 2025 AEP sales and retention, higher expected 2026 membership, and extended forecasts through 2030. Analyst Commentary Bullish analysts are pointing to refreshed models that run through 2030 as a key driver behind the higher price targets for Alignment Healthcare.Narrative Update • Jan 05
ALHC: Uneven Medicare Advantage Margin Recovery From 2026 Will Pressure Upside
Analysts have lifted their price target on Alignment Healthcare to US$21, citing expectations for a US$3 upside to fair value, supported by views of stronger revenue growth, improving profit margins, and a lower forward P/E multiple as Medicare Advantage margins potentially recover over time. Analyst Commentary Goldman Sachs has started coverage on Alignment Healthcare with a US$21 price target, framing the call within a broader view that Medicare Advantage margins could enter a recovery phase starting in 2026.Analysis Article • Dec 20
Investors Still Aren't Entirely Convinced By Alignment Healthcare, Inc.'s (NASDAQ:ALHC) Revenues Despite 25% Price Jump
Alignment Healthcare, Inc. ( NASDAQ:ALHC ) shareholders have had their patience rewarded with a 25% share price jump in...Narrative Update • Dec 14
ALHC: Margin Recovery From 2026 Will Shape Medicare Advantage Outlook
Analysts have raised their price target on Alignment Healthcare from $13.60 to $18.00 per share, citing expectations for accelerating Medicare Advantage growth, modestly higher long term revenue expansion, and improving margins as the industry enters a margin recovery phase starting in 2026. Analyst Commentary Recent coverage has highlighted Alignment Healthcare as a differentiated Medicare Advantage platform positioned to benefit from a multi year margin recovery across the sector starting in 2026.Narrative Update • Nov 29
ALHC: Margin Recovery in Medicare Advantage Will Offer New Upside and Risks
Analysts have slightly raised their price target for Alignment Healthcare from $20.88 to $21.04, citing expectations for a margin recovery in Medicare Advantage and an improved industry outlook. Analyst Commentary Recent coverage updates provide additional perspective on the outlook for Alignment Healthcare as analysts weigh both positive catalysts and ongoing risks in the managed care sector.Narrative Update • Nov 15
ALHC: Value-Based Medicare Advantage Will Drive Market Share Gains
Analysts have raised their price target for Alignment Healthcare by $0.42 to $20.88. They cite expectations of continued revenue growth and the company's value-based Medicare Advantage model as factors supporting ongoing market share gains.Narrative Update • Oct 31
ALHC: Margin Recovery Will Drive Medicare Advantage Market Share Gains
Analysts have raised their price target for Alignment Healthcare from $19.09 to $20.45 per share, citing anticipated margin improvements and a favorable outlook for its Medicare Advantage business. Analyst Commentary Bullish Takeaways Analysts highlight Alignment Healthcare's strong positioning within Medicare Advantage and foresee market share gains as value-based care accelerates in the sector.Analysis Article • Jul 06
An Intrinsic Calculation For Alignment Healthcare, Inc. (NASDAQ:ALHC) Suggests It's 21% Undervalued
Key Insights Alignment Healthcare's estimated fair value is US$17.25 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Jun 13
Should You Investigate Alignment Healthcare, Inc. (NASDAQ:ALHC) At US$15.08?
Alignment Healthcare, Inc. ( NASDAQ:ALHC ), might not be a large cap stock, but it received a lot of attention from a...Analysis Article • May 29
It Looks Like Shareholders Would Probably Approve Alignment Healthcare, Inc.'s (NASDAQ:ALHC) CEO Compensation Package
Key Insights Alignment Healthcare will host its Annual General Meeting on 5th of June Salary of US$817.3k is part of...Analysis Article • May 14
Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Alignment Healthcare, Inc. ( NASDAQ:ALHC ) shares have had a horrible month, losing 29% after a relatively good period...
New Narrative • Mar 21
AVA Integration And High Stars Ratings Set To Improve Future Margins
Significant membership growth outside California and high Stars ratings are driving revenue growth and enhancing market footprint.Analysis Article • Mar 20
Alignment Healthcare, Inc. (NASDAQ:ALHC) Soars 26% But It's A Story Of Risk Vs Reward
Despite an already strong run, Alignment Healthcare, Inc. ( NASDAQ:ALHC ) shares have been powering on, with a gain of...Analysis Article • Mar 06
Alignment Healthcare, Inc. (NASDAQ:ALHC) Shares Could Be 25% Below Their Intrinsic Value Estimate
Key Insights Alignment Healthcare's estimated fair value is US$20.95 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Feb 13
Should You Investigate Alignment Healthcare, Inc. (NASDAQ:ALHC) At US$14.52?
While Alignment Healthcare, Inc. ( NASDAQ:ALHC ) might not have the largest market cap around , it led the NASDAQGS...Analysis Article • Jan 17
Further Upside For Alignment Healthcare, Inc. (NASDAQ:ALHC) Shares Could Introduce Price Risks After 34% Bounce
The Alignment Healthcare, Inc. ( NASDAQ:ALHC ) share price has done very well over the last month, posting an excellent...Seeking Alpha • Jan 15
Alignment Healthcare: Growth For Growth's Sake
Summary Alignment Healthcare's stock has doubled since August 2023, driven by investor belief in a pivot towards profitability. However, Alignment's high Medical Benefits Ratio (MBR) of 89.3% and continued operating losses indicate the business model is not yet sustainably profitable. Furthermore, management's excessive equity compensation and insider selling raise concerns about alignment with shareholder interests. I continue to take a cautious view of the company. Maintain hold rating. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Alignment Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 4,257 | 20 | 460 | 0 |
| 31 Dec 25 | 3,949 | -1 | 442 | 0 |
| 30 Sep 25 | 3,637 | -21 | 417 | 0 |
| 30 Jun 25 | 3,336 | -51 | 398 | 0 |
| 31 Mar 25 | 3,002 | -91 | 383 | 0 |
| 31 Dec 24 | 2,704 | -128 | 370 | 0 |
| 30 Sep 24 | 2,468 | -144 | 354 | 0 |
| 30 Jun 24 | 2,232 | -153 | 344 | 0 |
| 31 Mar 24 | 2,013 | -157 | 327 | 0 |
| 31 Dec 23 | 1,824 | -148 | 307 | 0 |
| 30 Sep 23 | 1,720 | -158 | 305 | 0 |
| 30 Jun 23 | 1,624 | -163 | 300 | 0 |
| 31 Mar 23 | 1,528 | -146 | 292 | 0 |
| 31 Dec 22 | 1,434 | -150 | 296 | 0 |
| 30 Sep 22 | 1,371 | -140 | 290 | 0 |
| 30 Jun 22 | 1,304 | -146 | 291 | 0 |
| 31 Mar 22 | 1,246 | -179 | 300 | 0 |
| 31 Dec 21 | 1,168 | -195 | 291 | 0 |
| 30 Sep 21 | 1,112 | -180 | 264 | 0 |
| 30 Jun 21 | 1,066 | -123 | 226 | 0 |
| 31 Mar 21 | 1,002 | -70 | 189 | 0 |
| 31 Dec 20 | 959 | -23 | 156 | 0 |
| 31 Dec 19 | 757 | -45 | 110 | 0 |
Quality Earnings: ALHC has high quality earnings.
Growing Profit Margin: ALHC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALHC has become profitable over the past 5 years, growing earnings by 20.7% per year.
Accelerating Growth: ALHC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALHC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (17.4%).
Return on Equity
High ROE: ALHC's Return on Equity (9.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/17 03:48 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alignment Healthcare, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Sarah James | Barclays |
| Andrew Mok | Barclays |